Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dapsone: IMM completed enrollment of a double-blind, placebo controlled, 52-week, international Phase II trial (DAD2000) of dapsone in 201 patients aged 50-90 w

Immune Network Ltd. (CDNX:IMM; IMMKF), Vancouver, B.C.
Product:

Read the full 82 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE